Company intelligence / Profile preview

Applied Molecular Evolution

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Applied Molecular Evolution (AME) was a biotechnology company that pioneered the use of directed evolution to optimize protein and antibody therapeutics. The company's proprietary AMEsystem platform allowed for the rapid improvement of a drug's binding affinity, stability, and manufacturing efficiency by mimicking the natural process of selection. AME was acquired by Eli Lilly in 2004 for approximately $400 million to serve as a core component of Lilly's biologics strategy. Following the acquisition, AME's San Diego facility became a key site for Lilly's antibody discovery and optimization efforts.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyProteinRecombinant protein
Industry: Biotech

Partnerships

MedImmuneBristol Myers Squibb

Beyond the preview

Go deeper on Applied Molecular Evolution.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Applied Molecular Evolution.

Explore the full profile